Protagonist Therapeutics’ (PTGX) Buy Rating Reiterated at HC Wainwright
HC Wainwright reissued their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research note issued to investors on Monday,Benzinga reports. They currently have a $54.00 price target on the stock. A number of other equities analysts have also commented on the company. BMO Capital Markets assumed coverage on Protagonist Therapeutics […]
HC Wainwright reissued their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research note issued to investors on Monday,Benzinga reports. They currently have a $54.00 price target on the stock. A number of other equities analysts have also commented on the company. BMO Capital Markets assumed coverage on Protagonist Therapeutics […]
